Novartis/Nestle deal closes
This article was originally published in The Tan Sheet
Nestle completed its acquisition of Novartis Medical Nutrition July 1 following "the successful conclusion of the regulatory process," Nestle announces. The Novartis unit and its roughly 2,000 employees will be integrated into Nestle Nutrition, Nestle says. "The acquisition propels Nestle into a strong number two position globally in the fast-growing and lucrative healthcare nutrition market, helping to accelerate the profitable development of the overall nutrition business," the firm adds. Plans for the transaction were announced in December (1"The Tan Sheet" Dec. 18, 2006, p. 8)...
You may also be interested in...
Nestle looks to become the number two company in the healthcare nutrition field, including the infant formula market, with its planned $2.5 bil. acquisition of Novartis' Medical Nutrition unit
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.